drugset / Trial / NCT01355965
Autologous Redirected RNA Meso-CIR T Cells
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine the safety and manufacturing feasibility of IV autologous chimeric immune receptor (CIR) T cells transfected with anti-mesothelin messenger RNA (mRNA) expressing a single chain antibody variable fragment linked to the intracellular CD 3 zeta T cell receptor domain and the 4-1BB costimulatory domain.
Timeline
- Start
- 2011-05
- Primary completion
- 2015-07
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | therapeutic autologous lymphocytes | Cell therapy | 1e+08 cells | Intravenous |
| Subject | therapeutic autologous lymphocytes | Cell therapy | 1e+09 cells | Intravenous |